Parexel, a provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, has announced it has completed the purchase of the Natural Language Processing (NLP) technology assets and transfer of key personnel of Roam Analytics, Inc., a healthcare software company based in San Francisco, California. This strengthens Parexel’s commitment to leveraging Artificial Intelligence and Machine Learning to drive new innovations across drug development and life sciences.
Roam Analytics’ technology platform enables organizations to leverage any source of healthcare language data, from clinical notes to patient surveys, regulatory documents, marketing materials, telemedicine interactions, social media and more, to aim to improve operational workflows.
Financial terms of the agreement were not disclosed.
Read the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.